Physician profile
Kaiser Kabir
NPI 1346824745
$2,502.70
in general payments reported to CMS, 2019-2025
15 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $223 · 2024: $562 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.60 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.94 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $249.48 | 2025 | Livdelzi, Epclusa |
| E.R. Squibb & Sons, L.L.C. | $236.39 | 2022-2023 | Zeposia |
| Pfizer INC. | $211.84 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.77 | 2024-2025 | Entyvio, Eohilia |
| Mallinckrodt Hospital Products INC. | $130.20 | 2025 | Terlivaz |
| Janssen Scientific Affairs, LLC | $129.98 | 2024 | Stelara, Tremfya |
| Janssen Biotech, INC. | $126.00 | 2024 | Stelara, Tremfya |
| Genzyme Corporation | $123.61 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $116.10 | 2024 | |
| Madrigal Pharmaceuticals | $106.45 | 2025 | Rezdiffra |
| Amgen INC. | $102.98 | 2025 | Uplizna |
| Regeneron Healthcare Solutions, INC. | $102.06 | 2025 | Dupixent |
| Ardelyx, INC. | $25.30 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaiser Kabir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.